A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 15vPCV (Vaxneuvance, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 112 days).
The study duration per participant will be up to approximately 20 months. The study vaccines (either PCV21 or 15-valent pneumococcal vaccines) will be administered at approximately 2, 4, and 11 to 15 months of age or at approximately 2, 3, 4, and 11 to 15 months of age (for preterm infants). Routine pediatric vaccines will be given at the same timepoints, as per local practice / recommendations.
• There will be 5 (for full-term infants) or 6 (for preterm infants) study visits:
* Full-term infants: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 30 days, V04 at 11 months of age until 15 months of age, V05 separated from V04 by 30 days.
* Preterm infants: Visit (V)01, V02 separated from V01 by 30 days, V03 separated from V02 by 30 days, V04 separated from V03 by 30 days, V05 at 11 months of age until 15 months of age, V06 separated from V05 by 30 days.

Start Date22 May 2025

Sponsor / Collaborator

Sanofi

NCT06838000

/ RecruitingPhase 3

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).

Start Date28 Feb 2025

Sponsor / Collaborator

Sanofi Pasteur SA

NCT06824181

/ RecruitingPhase 3

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days).
The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations.
There will be 6 study visits:
Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

Start Date27 Feb 2025

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

100 Translational Medicine associated with Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

100 Patents (Medical) associated with Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

Literatures (Medical) associated with Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

31 Dec 2025·Human Vaccines & Immunotherapeutics

The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era

Review

Author: Chen, Chih-Jung ; Tsai, Ming-Han ; Chen, Chih-Ho ; Chen, Chyi-Liang ; Su, Lin-Hui ; Chiu, Cheng-Hsun

Two pneumococcal conjugate vaccines, PCV15 and PCV20, were licensed in June 2021. PCV15 includes two additional serotypes (22F, 33F) beyond those in PCV13, while PCV20 adds seven more (8, 10A, 11A, 12F, 15B, 22F, 33F), covering approximately 30% of invasive pneumococcal disease (IPD) cases in adults. In June 2023, the US CDC's Advisory Committee on Immunization Practices (ACIP) recommended either PCV15 or PCV20 for all children aged < 5 years and children aged 2‒18 years with risk conditions. In June 2024, the FDA approved PCV21 for adults ≥ 18 years. In October 2024, ACIP recommended either PCV20 or PCV21 alone or PCV15 with PPSV23 for adults ≥ 50 years or 19-49 years with risk conditions. These advancements highlight the evolving landscape of pneumococcal vaccination. This review examines the molecular epidemiology of pneumococcal infections, advancements in diagnostic methods, and the anticipated public health impact of these vaccines in reducing pneumococcal disease burden.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Economic evaluation of PCV21 in vaccine-naïve adults aged 19–64 years with underlying medical conditions in the United States

Article

Author: Owusu-Edusei, Kwame ; Yi, Zinan ; Elbasha, Elamin H.

INTRODUCTION:

This study aimed to estimate the incremental health and economic outcomes associated with the use of PCV21 (Capvaxive) in vaccine-naive adults aged 19-64 years with underlying medical conditions in the United States (US).

METHODS:

A static multi-cohort state-transition Markov model was utilized, drawing on data from published literature and publicly available databases and reports, comparing PCV21 (intervention) versus PCV20 or PCV15 + PPSV23 (comparator) from a societal perspective with a lifetime horizon. The target population consisted of vaccine-naive adults aged 19-64 years classified as at-risk (AR) or high-risk (HR). Key outcome measures included undiscounted clinical cases: invasive pneumococcal disease (IPD), inpatient and outpatient non-bacteremic pneumococcal pneumonia (NBPP), post-meningitis sequelae (PMS), deaths from IPD and inpatient NBPP, as well as discounted quality-adjusted life years (QALYs), and total costs (in 2023 USD), with the incremental cost-effectiveness ratios (ICERs) reported as $/QALY gained. Costs and QALYs were discounted at 3% per year. Deterministic and probabilistic sensitivity analyses were conducted.

RESULTS:

The analysis indicated that the V116 strategy prevented a substantial number of cases and deaths compared to the PCV20 or PCV15 + PPSV23 strategies among vaccine-naive AR/HR adults aged 19-49 and 50-64 years. For instance, the use of PCV21 was projected to reduce IPD cases by 1,450 and 4,232, respectively, in the two age groups when compared with PCV20. The estimated ICERs for both age groups were found to be cost-saving when compared to both PCV20 and PCV15 + PPSV23. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings, with over 95% of simulations yielding cost-saving results and all estimated ICERs remaining below $10,000/QALY gained.

CONCLUSIONS:

The findings suggest that the use of PCV21 (Capvaxive) in adults aged 19-64 years with underlying medical conditions in the US can prevent a significant number of pneumococcal disease cases and deaths while demonstrating favorable economic outcomes across various scenarios.

16 Jun 2025·Emerging Microbes & Infections

The rise of serotype 8 is associated with lineages and mutations in the capsular operon with different potential to produce invasive pneumococcal disease.

Article

Author: Sempere, Julio ; Domenech, Mirian ; Llamosí, Mirella ; García, Ernesto ; González-Díaz, Aída ; Yuste, Jose ; Úbeda, Aída ; Sanz, Juan Carlos ; Pérez-García, Covadonga ; Ardanuy, Carmen

Despite conjugate vaccine introduction to prevent invasive pneumococcal disease (IPD), serotype replacement by non-vaccine serotypes is a constant concern. In this study, we elucidate the rise of serotype 8 causing IPD in Spain. We evaluated isolates received during the period 2008-2023 including whole genome sequencing characterization and host-pathogen interaction studies. Serotype 8 has emerged as one of the most prevalent serotypes causing IPD in both children and adults. CC53/GPSC3 carrying pspC 6.11 was the dominant lineage in recent years, displaying increased adhesion to lung cells, enhanced biofilm formation, higher factor H recruitment, improved phagocytosis evasion, and greater virulence in a mice pneumonia model than other co-circulating lineages which could explain its predominance. Morphologically, serotype 8 strains exhibit two appearances on blood agar plates: mucoid colonies, and non-mucoid variants. Molecular characterization revealed that non-mucoid variants harbor mutations in the wchA gene and/or others within the capsular operon, leading to increased adhesion and biofilm formation, albeit with reduced immune evasion capacity. Serotype 8 has become a major cause of IPD, with CC53/GPSC3 as the dominant lineage due to its pathogenic advantages. The versatility of the capsular operon contributes to its success in causing IPD. The use of vaccines with broader coverage, such as PCV20 or PCV21, containing this serotype, may offer an effective strategy to ameliorate the impact on IPD by serotype 8.

News (Medical) associated with Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

21 May 2025

·www.prnewswire.com

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent of its vaccine, Prevnar 13. Continue Reading SK bioscience L HOUSE manufacturing plant However, the Supreme Court ruled that the individual conjugates comprising PCV13 do not fall within the scope of Pfizer's patent claims, thereby upholding the lower court's ruling in favor of SK bioscience. The Court also confirmed that the production and supply of PCV13 finished products for research purposes did not constitute patent infringement. SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been prohibited from manufacturing and selling the vaccine in Korea until 2027, when the related patents set to expire. Following the ruling, SK bioscience now plans to initiate new business in pneumococcal conjugate vaccines by exporting individual components of PCV13 to countries with high vaccine demand, such as those in Southeast Asia and Latin America. Technology transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine market. From 2027, the company will be able to manufacture and sell SKYPneumo domestically. In addition, the company is developing a 21-valent pneumococcal conjugate vaccine with global pharmaceutical company Sanofi, which entered Phase 3 global clinical in late 2024. Simultaneously, the two companies are also working on a next-generation pneumococcal vaccine that is expected to offer broader protection than current options. The global pneumococcal vaccine market continues to grow. According to Global Market Insights, the market is projected to grow at a compound annual rate of approximately 5.6% to reach USD 15.1 billion (approximately KRW 21.55 trillion) by 2034. This growth is driven by expanded vaccination programs and support from governments and international organizations like WHO and Gavi. SK bioscience's strong track record in public vaccine supply and cooperation with global health organizations positions it well for future expansion. Jaeyong Ahn, CEO of SK bioscience, said, "This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds new opportunity. We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth." Meanwhile, SK bioscience recently secured a definitive legal victory in a patent invalidation suit against Moderna, successfully challenging the biotech giant's Korean patent related to messenger RNA (mRNA) vaccine technology. The contested patent covers 'modified nucleosides, nucleotides, and nucleic acids and their uses.' This case, which invalidated the only registered mRNA manufacturing patent in Korea, regarded as a major step in reducing patent-related risks and removing barriers to innovation for domestic companies engaged in mRNA research and development. About SK bioscience SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. - SK bioscience Website - SK bioscience Linkedin Contact SK bioscience Communications Team Changhyun Jin ([email protected]) Jeannie S. Pak ([email protected]) SOURCE SK bioscience WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccinePatent InfringementmRNAPhase 3

30 Jan 2025

·www.fiercebiotech.com

Sanofi cuts programs tied to multibillion-dollar deals from pipeline

Sanofi disclosed removals from its pipeline alongside the progress of other molecules. \n Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, Principia Biopharma and Synthorx.The French drugmaker added the BTK inhibitor tolebrutinib to its pipeline by acquiring Principia for $3.7 billion. Facing down skepticism, Sanofi guided the asset to mixed phase 3 data last year, with the win in one form of multiple sclerosis offset by failures in another form of the disease. The company removed the relapsing multiple sclerosis program from its pipeline but plans to file for approval in another setting.Sanofi removed three assets from its phase 1 pipeline. Pegenzileukin, the IL-2 candidate Sanofi picked up through its $2.5 billion takeover of Synthorx, was one of the assets affected by the clearout. The molecule suffered a setback in 2022, triggering a 1.6 billion euro ($1.7 billion) impairment, but Sanofi kept going.The drugmaker began a phase 1/2 program in 2023 to optimize the dose schedule for the treatment of solid tumors. Sanofi listed the study of the candidate, which is also called SAR444245 and THOR-707, in “cancer, in combination” among the programs removed from phase 1 in the fourth quarter. The other two early-phase removals affected nanobodies, the platform technology Sanofi acquired in its 3.9 billion euro ($4.1 billion) takeover of Ablynx. One of the removed drug candidates, SAR445611, is an anti-CX3CR1 nanobody that Sanofi was developing in an inflammatory indication. The second jettisoned molecule is SAR444200, a GPC3-based nanobody T-cell engager that Sanofi was testing in solid tumors.\"Sanofi continues to prioritize our pipeline to focus on medicines and vaccines that deliver the greatest value for patients,\" a company spokesperson told Fierce Biotech in an emailed statement. \"That\'s why we\'ve made the decision to discontinue these select programs where we believe we cannot deliver meaningful value to patients.\"Sanofi disclosed the removals alongside the progress of other molecules. SP0202 advanced into phase 3, furthering Sanofi’s push to bring the SK bioscience-partnered 21-valent pneumococcal conjugate vaccine candidate to market. Sanofi recently agreed to pay 50 million euros ($52 million) upfront to expand its pneumococcal vaccine collaboration with SK.When it comes to dealmaking this year, Sanofi\'s CFO François Roger said the French pharma would be looking out for companies in the value range of 2 billion euros to 5 billion euros. “We will continue to explore external growth opportunities to strengthen our four existing therapeutic areas and potentially cover white spaces,” Roger said on an earnings call with analysts this morning. “We don\'t feel any pressure to go crazy on M&A and BD, so we will remain very disciplined while having the opportunity to compliment whatever we have in our pipeline.”Editor\'s note: This article has been updated with a statement from Sanofi.

AcquisitionVaccinePhase 3Phase 1

23 Dec 2024

·www.fiercebiotech.com

Sanofi pays SK bioscience €50M as children\'s pneumococcal vaccine enters phase 3

The partnership between Sanofi and SK bioscience dates back to 2014, when the French pharma paid $23 million upfront to get the ball rolling on vaccine development.\n Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3.The move follows a phase 2 win last year for the candidate, a 21-valent pneumococcal conjugate vaccine previously called GBP410 and now renamed PCV21, which demonstrated comparable immunogenicity to a control vaccine.By including 21 serotypes, the partners aim to offer broader coverage than the current approved pneumococcal conjugate vaccines for children. Sanofi announced Monday morning that it has now launched the shot into a phase 3 study, making it the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a late-stage study in infants and toddlers.Sanofi and SK will co-fund the research and development costs, with Sanofi also paying SK the 50 million euro upfront fee. An undisclosed amount of development and commercial milestone payments could follow. Should PCV21 make it to market, Sanofi will commercialize the vaccine worldwide, except for in SK’s home turf of South Korea.“Given the vast unmet public health needs in [invasive pneumococcal disease], we’re delighted to expand this collaboration and continue our pursuit of innovative work in PCV,” Thomas Triomphe, Sanofi\'s head of vaccines, said in the Dec. 23 release.“Our collaboration leverages SK bioscience’s capabilities and Sanofi’s expertise in developing and bringing innovative vaccines to people worldwide with the collective aim of reducing the global impact of pneumococcal disease,” Triomphe added. The partnership between Sanofi and SK dates back to 2014, when the French pharma paid $23 million upfront to get the ball rolling on vaccine development.There are currently two FDA-approved pneumococcal vaccines for children—Merck & Co.’s 15-valent Vaxneuvance and Pfizer’s 20-valent Prevnar 20.Sanofi isn’t the only Big Pharma hoping to expand the range of serotypes available in pneumococcal vaccines. GSK had been working on a 24-valent candidate acquired via its $2.1 billion acquisition of Affinivax but revealed in October that it had axed the asset. In June, Merck’s 21-valent Capvaxive became the first pneumococcal vaccine specifically designed for adults to receive FDA approval.Then, in September, Vaxcyte unveiled what analysts called “stunning” phase 1/2 data in adults for its 31-valent candidate that, if replicated in a large pivotal study, could pose a serious threat to Prevnar 20. A separate phase 2 trial of Vaxcyte’s shot in infants has recently launched.

$Sanofi pays SK bioscience €50M as children\'s pneumococcal vaccine enters phase 3$

Phase 2Phase 3VaccineAcquisitionClinical Result

100 Deals associated with Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Vaccination	Phase 3	United States	Sanofi	27 Feb 2025
Vaccination	Phase 3	Chile	Sanofi	27 Feb 2025
Vaccination	Phase 3	Philippines	Sanofi	27 Feb 2025
Pneumococcal Infections	Phase 3	South Korea	Sanofi Pasteur SA	18 Dec 2024
Chickenpox	Phase 2	United States	Sanofi Pasteur SA	22 May 2020
Chickenpox	Phase 2	Canada	Sanofi Pasteur SA	22 May 2020
Chickenpox	Phase 2	Honduras	Sanofi Pasteur SA	22 May 2020
Chickenpox	Phase 2	Puerto Rico	Sanofi Pasteur SA	22 May 2020
Diphtheria	Phase 2	United States	Sanofi Pasteur SA	22 May 2020
Diphtheria	Phase 2	Canada	Sanofi Pasteur SA	22 May 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04398706 (CTgov)	Phase 2	Diphtheria \| Hepatitis B \| Pneumonia ... View more	852	Pentacel+SP0202-IIb+Prevnar 13 (Stage I: Group 1 SP0202-IIb)	veuafjczvy = sfvrhzyolq dhydqzlwcb (fxppcoityj, kvssuvzkbo - sokmbcrypa) View more	-	12 Nov 2024
				Pentacel+SP0202-VI+Prevnar 13 (Stage I: Group 2 SP0202-VI)	veuafjczvy = rqfoynooze dhydqzlwcb (fxppcoityj, amkcmuqrve - czxewslpyo) View more
NCT04583618 (CTgov)	Phase 2	Vaccination	750	SP0202-IIb (Group 1: SP0202-IIb)	lqnhyxzgrq(vzufayvljw) = lmybyemxfi zzeirmhjvb (gbmixebiyd, wsmybskect - iiucgvbfqt) View more	-	27 Aug 2024
				SP0202-VI (Group 2: SP0202-VI)	lqnhyxzgrq(vzufayvljw) = gzvcrttwaj zzeirmhjvb (gbmixebiyd, ivlxtdtuji - gbpjcuiizt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Next-generation pneumococcal conjugate vaccine (Sanofi/SK Bioscience)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation